ATE246937T1 - Verwendung von threalose zur stabilisierung von einem flüssigen impfstoff - Google Patents

Verwendung von threalose zur stabilisierung von einem flüssigen impfstoff

Info

Publication number
ATE246937T1
ATE246937T1 AT00912734T AT00912734T ATE246937T1 AT E246937 T1 ATE246937 T1 AT E246937T1 AT 00912734 T AT00912734 T AT 00912734T AT 00912734 T AT00912734 T AT 00912734T AT E246937 T1 ATE246937 T1 AT E246937T1
Authority
AT
Austria
Prior art keywords
liquid vaccine
threalose
stabilization
vaccine composition
liquid
Prior art date
Application number
AT00912734T
Other languages
English (en)
Inventor
Graf Sandrine Lentsch
Jean-Rene Cartier
Original Assignee
Aventis Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pasteur filed Critical Aventis Pasteur
Application granted granted Critical
Publication of ATE246937T1 publication Critical patent/ATE246937T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
AT00912734T 1999-03-23 2000-03-23 Verwendung von threalose zur stabilisierung von einem flüssigen impfstoff ATE246937T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9903765A FR2791895B1 (fr) 1999-03-23 1999-03-23 Utilisation de trehalose pour stabiliser un vaccin liquide
PCT/FR2000/000730 WO2000056365A1 (fr) 1999-03-23 2000-03-23 Utilisation de trehalose pour stabiliser un vaccin liquide

Publications (1)

Publication Number Publication Date
ATE246937T1 true ATE246937T1 (de) 2003-08-15

Family

ID=9543654

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00912734T ATE246937T1 (de) 1999-03-23 2000-03-23 Verwendung von threalose zur stabilisierung von einem flüssigen impfstoff

Country Status (11)

Country Link
EP (1) EP1163008B1 (de)
JP (1) JP2002540079A (de)
AT (1) ATE246937T1 (de)
AU (1) AU3438900A (de)
CA (1) CA2366869A1 (de)
DE (1) DE60004496T2 (de)
DK (1) DK1163008T3 (de)
ES (1) ES2200845T3 (de)
FR (1) FR2791895B1 (de)
PT (1) PT1163008E (de)
WO (1) WO2000056365A1 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2283012T3 (es) 1996-01-04 2007-10-16 Novartis Vaccines And Diagnostics, Inc. Bacterioferritina de helicobacter pylori.
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
ES2608048T3 (es) 2002-10-11 2017-04-05 Glaxosmithkline Biologicals Sa Vacunas polipeptídicas para protección amplia contra linajes meningocócicos hipervirulentos
CA2514328C (en) 2003-01-30 2020-01-14 Chiron Srl Injectable vaccines against multiple meningococcal serogroups
DK1961426T3 (da) 2003-10-02 2011-08-08 Novartis Ag Kombinationsvacciner mod meningitis
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
GB0406013D0 (en) 2004-03-17 2004-04-21 Chiron Srl Analysis of saccharide vaccines without interference
AU2007251122B2 (en) * 2006-05-12 2013-01-10 Bharat Biotech International Limited A composition useful as a vaccine
ES2387582T3 (es) 2006-09-07 2012-09-26 Glaxosmithkline Biologicals S.A. Vacuna de combinación con cantidades reducidas del antígeno del virus de la polio
CA2685506A1 (en) 2007-05-02 2008-11-13 Glaxosmithkline Biologicals S.A. Vaccine
CA2699435A1 (en) 2007-09-14 2009-03-19 Sanofi Pasteur Biologics Co. Pharmaceutical compositions containing clostridium difficile toxoids a and b
EP2106788A1 (de) 2008-04-04 2009-10-07 Ipsen Pharma Flüssige und lyophilisierte Formulierungen
AU2010352695B2 (en) 2009-09-30 2014-08-21 Glaxosmithkline Biologicals S.A. Conjugation of Staphylococcus aureus type 5 and type 8 capsular polysaccharides
JP2013521327A (ja) 2010-03-10 2013-06-10 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組成物
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
GB201016969D0 (en) 2010-10-08 2010-11-24 Genome Res Ltd Expression system
US20120294894A1 (en) 2011-05-20 2012-11-22 Nitto Denko Corporation Pharmaceutical composition and method for producing the same
CN103917245B (zh) 2011-09-14 2017-06-06 葛兰素史密丝克莱恩生物有限公司 用于制备糖‑蛋白质糖缀合物的方法
EP2788477A2 (de) 2011-12-07 2014-10-15 Institut Pasteur Identifizierung des porcinen parecho-like virus und anwendungen
MX2014014067A (es) 2012-05-22 2015-02-04 Novartis Ag Conjugado de serogrupo x de meningococo.
FR2992656B1 (fr) * 2012-07-02 2016-10-07 Sanofi Pasteur Procede de production d'antigenes haemophilus influenzae type b
WO2014009971A2 (en) * 2012-07-07 2014-01-16 Bharat Biotech International Limited Non-alcoholic vaccine compositions free from animal- origin and process for preparation thereof
JP6266000B2 (ja) 2012-10-03 2018-01-24 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組成物
US10564150B2 (en) * 2012-12-28 2020-02-18 Cellestis Limited Cell mediated immune response assay
BE1024634B1 (fr) 2016-04-05 2018-05-14 Gsk Vaccines S.R.L. Compositions immunogenes
CN109890413B (zh) 2016-09-02 2024-04-16 赛诺菲巴斯德股份有限公司 脑膜炎奈瑟氏菌疫苗
WO2018048869A1 (en) 2016-09-06 2018-03-15 Bioventures, Llc Compositions and methods for generating reversion free attenuated and/or replication incompetent vaccine vectors
US20180264095A1 (en) 2017-03-03 2018-09-20 Treos Bio Zrt Population-based immunogenic peptide identification platform
EP3370065A1 (de) 2017-03-03 2018-09-05 Treos Bio Kft Immunogene peptide
EP3369431A1 (de) 2017-03-03 2018-09-05 Treos Bio Kft Impfstoff
GB201814362D0 (en) 2018-09-04 2018-10-17 Treos Bio Zrt Composition and process for preparing vaccine
MA53543A (fr) 2018-09-04 2021-07-14 Treos Bio Ltd Vaccins peptidiques
CA3117867A1 (en) 2018-11-06 2020-05-14 Glaxosmithkline Biologicals Sa Immunogenic compositions
GB201908332D0 (en) 2019-06-11 2019-07-24 Univ Oxford Innovation Ltd Assays and inhibitors of oxygen-dependent N-terminal oxidation
GB202004974D0 (en) 2020-04-03 2020-05-20 Treos Bio Ltd Coronavirus vaccine
CA3174505A1 (en) 2020-04-03 2021-10-07 Zsolt CSISZOVSZKI Coronavirus vaccine
WO2022268916A2 (en) 2021-06-23 2022-12-29 Ose Immunotherapeutics Pan-coronavirus peptide vaccine
GB202109082D0 (en) 2021-06-24 2021-08-11 Univ Oxford Innovation Ltd Polypeptides and uses thereof
WO2023148333A1 (en) 2022-02-03 2023-08-10 CeCaVa GmbH & Co. KG Co-vaccination with cd4 and cd8 antigens
GB202208695D0 (en) 2022-06-14 2022-07-27 Univ Oxford Innovation Ltd Antibacterials

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2748132A1 (de) * 1977-10-27 1979-05-03 Behringwerke Ag Stabilisator fuer polysaccharid
US4902506A (en) * 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
IL78775A (en) * 1985-05-15 1992-06-21 Biotech Australia Pty Ltd Oral vaccines
ES2137310T3 (es) * 1993-05-17 1999-12-16 Akzo Nobel Nv Vacuna contra una infeccion por streptococcus suis.
DE69530196T2 (de) * 1994-06-02 2003-11-20 Elan Drug Delivery Ltd Methode zum verhindern der aggregation von proteinen/peptiden bei rehydratation oder auftauen
DK0939648T3 (da) * 1996-09-26 2008-02-11 Merck & Co Inc Rotavirusvaccineformuleringer
US6210683B1 (en) * 1997-09-05 2001-04-03 Merck & Co., Inc. Stabilizers containing recombinant human serum albumin for live virus vaccines

Also Published As

Publication number Publication date
DK1163008T3 (da) 2003-11-17
PT1163008E (pt) 2003-12-31
EP1163008B1 (de) 2003-08-13
EP1163008A1 (de) 2001-12-19
WO2000056365A1 (fr) 2000-09-28
ES2200845T3 (es) 2004-03-16
AU3438900A (en) 2000-10-09
DE60004496T2 (de) 2004-04-08
JP2002540079A (ja) 2002-11-26
CA2366869A1 (en) 2000-09-28
FR2791895A1 (fr) 2000-10-13
DE60004496D1 (de) 2003-09-18
FR2791895B1 (fr) 2001-06-15

Similar Documents

Publication Publication Date Title
ATE246937T1 (de) Verwendung von threalose zur stabilisierung von einem flüssigen impfstoff
UA93855C2 (ru) Вакцина, способствует росту, базирующейся ha нейтрализующем эпитопе
IL210392A0 (en) Antibodies that bind to tgf-?? binding proteins with an affinity of 106m-1 and uses thereof
DE60100473D1 (de) Verwendung von neurotoxinen in medikamenten zur behandlung von thyroidstörungen
DE69936948D1 (de) Virusenthaltende Zusammensetzungen und Methoden zur Konzentration von Viruspräparaten
ATE394536T1 (de) Textilweichmacherzusammensetzungen und verfahren zur stabilisierung von textilweichmacherzusammensetzungen
EP1408986A4 (de) Proteomimetische verbindungen und verfahren
YU9404A (sh) Multimerna, usmerena kontrastna sredstva na bazi peptida
DE69833134D1 (de) Verwendung aliphatischer amine zur verminderung von oxalat
DE69431404D1 (de) Verfahren zur mikroverkapselung von antigenen und verwendung der zusammensetzungen als impfstoffe
DE69842240D1 (de) Gerät zur verankerung von objekten an knochen
GEP20043349B (en) Methods of Controlling Cutworm Pests
DE59804785D1 (de) Verbessertes Verfahren zur Stabilisierung von Proteinen
DE60007657D1 (de) Verfahren zur stabilisierung von siloxan-verbindungen
DE69823711D1 (de) Verfahren zur Stabilisierung von Siloxanpolymeren
ATE424217T1 (de) Zusammensetzungen zur steigerung der effizienz von impfstoffen unter verwendung von chemokinen
DE69835813D1 (de) Verfahren zur kultivierung von zellen und zur vermehrung von viren
ATE274185T1 (de) Verfahren und zusammensetzungen zur trennung von biologischen makromolekülen
ATE505538T1 (de) Dna-vektoren
ATE313628T1 (de) Klonierung und expression von haemophilus somnus transferrin-bindenden proteinen
ATE340249T1 (de) Produkt zur proteinstabilisierung von weinen
SE9604439D0 (sv) New receptor
DE69805298D1 (de) Verbessertes verfahren zur kryopreservierung von pferdeembryonen
ATE359811T1 (de) Verwendung von trehalose produzierenden prokaryotischen zellen als impfstoffe
EP1664094A4 (de) Kleine hitzeschock proteine (shsps) enthaltende zusammensetzungen zum schutz vor proteinabbau und verfahren zur zweidimensionalen gelelektrophorese unter anwendung der shsps

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1163008

Country of ref document: EP

REN Ceased due to non-payment of the annual fee